- Fast shipping in USA & Europe
- Made in Switzerland
- info@cellpeptides.com
$95.00
Semaglutide is a synthetic version of GLP-1 (Glucagon-Like Peptide-1), a naturally occurring hormone that plays a key role in regulating blood sugar and appetite. Originally developed to treat type 2 diabetes, Semaglutide helps the body release insulin when needed and suppresses glucagon — the hormone that raises blood sugar — all in a glucose-dependent manner. This means it supports more stable blood sugar levels without the risk of sudden drops.
But the benefits of Semaglutide go beyond blood sugar control. Research has shown that it may also improve cardiovascular, liver, and lung function, and there’s growing interest in its potential to slow the progression of Alzheimer’s disease. One of its most well-known effects is appetite suppression — Semaglutide delays gastric emptying and slows digestion, which helps people feel full longer and naturally eat less.
With its broad impact on metabolism, inflammation, and neurological health, Semaglutide is increasingly being looked at as more than a diabetes drug — it’s becoming a key player in weight management, longevity, and metabolic optimization.
✔ Pharmaceutical-Grade Purity – Manufactured to ≥99% purity standards.
✔ Independent Lab Testing – Verified for identity, composition, and concentration.
✔ Fast, Secure Delivery – Insured global shipping with full tracking.
✔ Flexible Payment Options – Pay via credit card, bank transfer, or cryptocurrency.
✔ Specialized Support – Our team is ready to assist with technical or ordering questions.
Semaglutide helps manage blood sugar levels in persons experiencing Type-2 diabetes. The medication stimulates insulin release and lowers blood glucose levels. Semaglutide also acts to suppress the release of glucagon (hormone that increases blood sugar levels) to aid better control against hyperglycemia (high blood sugar levels).
The FDA’s approval of Semaglutide (under the Wegovy brand name) boosted its profile for use across weight loss programs. The medication supports weight loss by helping to suppress appetite that leads to lower food intake. Semaglutide acting to reduce appetite helps persons experiencing obesity or other health problems caused by being overweight.
Semaglutide offers identical support available from its branded and more expensive alternatives. It is a cheaper, equally-effective option to branded variants sold through prescriptions.
People who need affordable options to Ozempic for off-label uses prefer Semaglutide for weight loss programs.
Ongoing research continues to examine Semaglutide in treating conditions like non-alcoholic fatty liver disease (NAFLD). The peptide shows promise in lowering risks of heart disease and for improvement of cardiovascular health. It has shown success in boosting how insulin acts against rising sugar levels and could help ease or eliminate effects of related health conditions.
Semaglutide is available as:
Semaglutide copycats the action of GLP-1, which naturally occurs in the intestines after consuming food. The peptide’s mechanism of action works to increase the secretion of insulin when blood sugars spike. It also helps to keep glucagon under control and effectively stabilizes glucose levels.
Semaglutide also works to slow emptying of the stomach and reduces appetite significantly. Users of the peptide will feel a sense of fullness for much longer, and this will help reduce their food intake and lower risks of staying overweight.
Semaglutide acts to reduce HbA1c levels (long-term blood glucose indicator) and reduces chances of hyperglycemia (high blood sugar levels).
Semaglutide functions to suppress appetite to encourage lower intake of calories that may ramp up fat buildup. Studies show that individuals can lose over 10% of body weight within 15 months of treatment using this peptide.
Semaglutide helps boost lipid profiles that support better metabolic health among users.
Anyone keen to maintain reduce appetite while dealing with obesity or weight-related problems can use Semaglutide.
Semaglutide promotes the release of insulin and reduction of glucagon to improve resistance against diabetes.
Users of Semaglutide will notice reduced appetite within the first month of treatment. The early effects of this peptide aids weight shedding shortly after getting on a dosing plan.
Major improvements in blood sugar level control become evident within the first 5 months of using Semaglutide. Patients may experience reduced episodes of hyperglycemia and lower blood sugar readings within this time.
Pronounced results that come with significant weight reduction and management of diabetes will start to show after 6 to 12 months of treatment.
The starting dose for Semaglutide is usually 0.2mg per week. Incremental doses may be necessary to improve the effects of this medication over time.
Take breaks during dosing cycles as prescribed by your healthcare provider.
Semaglutide is relatively safe; however, it could lead to some side effects during dosing. Common side effects that may arise from using Semaglutide include:
However, these symptoms dissipate over time as the body begins to adapt to doses. Healthcare practitioners could apply incremental dosing to administer Semaglutide and reduce or eliminate the effects of the peptide.
Ozempic and Wegovy both contain Semaglutide as their main active ingredient; however, their approvals are for different uses. Ozempic mainly works to manage Type-2 diabetes while Wegovy is approved for weight management to assist persons dealing with obesity or other related issues.
Weight loss results aided by Semaglutide become evident after few weeks of treatment. Better results will start to show from 3 to 6 months after using this medication in controlled doses. Obvious loss of fat and reduction of obese appearance in Semaglutide users will be easy to see after a year of use.
Semaglutide has primary approval to manage diabetes and for weight loss; however, using it for other conditions still needs research attention. Some studies suggest that Semaglutide could have potential uses in treating non-alcoholic fatty liver disease (NAFLD) and some cardiovascular issues.
Using Semaglutide for such purposes is purely experimental and should be done under supervision of a qualified healthcare practitioner.
Semaglutide does not cause low blood sugar (hypoglycemia) unless combined with other medications that lower blood sugar like insulin or sulfonylureas. Consult a healthcare provider if you plan to combine Semaglutide with other medications that lower blood sugar.
The effects of Semaglutide on pregnant women and their unborn children is unknown. Women of childbearing age should use contraceptives while on Semaglutide medication and immediately consult a doctor if pregnancy is suspected while dosing on this peptide.
Take the missed dose of Semaglutide within 5 days. If the missed dose has been over 5 days, you should skip it and take your next scheduled dose. Double-dosing on Semaglutide to make up for a missed shot can have negative effects on your health needs.
Many people consider Semaglutide an affordable option to expensive branded products like Ozempic or Wegovy. Semaglutide is the active ingredient in Ozempic and can be used off-label for weight loss when other options are unavailable.
Amaro, A., Sugimoto, D. & Wharton, S., 2022. Efficacy and safety of Semaglutide for weight management: evidence from the STEP program. Postgraduate Medicine, 134(sup1), pp.5–17. https://doi.org/10.1080/00325481.2022.2147326.
Doggrell, S.A., 2018. Semaglutide in type 2 diabetes – is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? Expert Opinion on Drug Metabolism & Toxicology, 14(3), pp.371–377. https://doi.org/10.1080/17425255.2018.1441286.
Goldenberg, R.M. & Steen, O., 2019. Semaglutide: Review and place in therapy for adults with type 2 diabetes. Canadian Journal of Diabetes, 43(2), pp.136–145. https://doi.org/10.1016/j.jcjd.2018.05.008.
Hughes, S. & Neumiller, J.J., 2020. Oral Semaglutide. Clinical Diabetes, 38(1), pp.109–111. https://doi.org/10.2337/cd19-0079.
Phillips, A. & Clements, J.N., 2022. Clinical review of subcutaneous Semaglutide for obesity. Journal of Clinical Pharmacy and Therapeutics, 47(2), pp.184–193. https://doi.org/10.1111/jcpt.13574.
Singh, G., Krauthamer, M. & Bjalme-Evans, M., 2022. Wegovy (Semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1), pp.5–13. https://doi.org/10.1136/jim-2021-001952.
U.S. Food and Drug Administration (FDA), 2018. Drug Approval Package: Ozempic (Semaglutide) Injection.
Amino Acid Sequence: | His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ |
---|---|
Molecular Weight: | 4,113.64 g/mol |
Molecular Formula: | C₁₈₇H₂₉₁N₄₅O₅₉ |
CAS Number: | 910463-68-2 |